Her-2/neu overexpression/amplification has been reported in ovarian cancer and is associated with poor clinical outcome. The aim of our study is to evaluate expression of Her-2/neu in surface epithelial ovarian carcinomas (SEOC) and its relation with different clinicopathological parameters. This retrospective study was carried out on 94 cases of SEOC retrieved from archive of pathology lab at Mansoura Oncology Center during the period from 2010 to 2017.All available H & E stained slides were examined. Immunohistochemical staining was performed and Her-2/neu positivity was assessed. Forty-seven cases were of score (0), twenty-eight cases were of score (1), eleven cases were of score (2) and eight cases were of score (3). Three out of the 8 positive cases were serous cystadenocarcinomas and five were of high tumor grade. We found no statistically significant relation between Her-2/neu expression and any of the clinicopathological features of the tumors. We observed non-statistically significant higher percentage of Her-2/neu negativity among serous carcinoma, endometrioid carcinoma and mucinous carcinoma. On the other hand, 50% of clear cell carcinoma were Her-2/neu positive. In conclusion, Her-2/neu is overexpressed in 8.5% of SEOC. Serous type and high grade carcinomas showed the maximum number of Her-2/neu positive cases. There was no statistically significant association between Her-2/neu overexpression and any of the clinicopathological features.
 

Download Full Text - PDF